Yang YF, Yuan L, Li XY, Liu Q, Jiang WJ, Jiao TQ, Li JQ, Ye MY, Niu Y, Nan Y. Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation. World J Diabetes 2024; 15(9): 1942-1961 [PMID: 39280184 DOI: 10.4239/wjd.v15.i9.1942]
Corresponding Author of This Article
Yi Nan, MD, Professor, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080011@nxmu.edu.cn
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Sep 15, 2024; 15(9): 1942-1961 Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1942
Table 1 Primer information
Gene
Sequence
Product length (bp)
TP53
F:5’-GGCTCCGACTATACCACTATCCAC-3’
129
R:5'GTCCCGTCCCAGAAGATTCCC-3'
AKT1
F:5’AACTTCTCAGTGGCACAATGTCAG-3’
71
R:5’CAGCGGATGATGAAGGTGTTGG-3’
c-Jun
F:5'TCTACGACGATGCCCTCAACG-3'
99
R:5’GGTTCAAGGTCATGCTCTGCTTC-3’
Caspase-3
F:5’CGGTATTGAGACAGACAGTGGAAC-3’
90
R:5’GCGGTAGAGTAAGCATACAGGAAG-3’
MAPK1
F:5'CTTCCAACCTCCTGCTGAACAC-3'
117
R:5’GCGTGGCTACATACTCTGTCAAG-3’
MAPK3
F:5’CGCATCACAGTAGAGGAAGCAC-3’
72
R:5’CACTGGTTCATCTGTCGGATCATAG-3’
GAPDH
F:5’-CAAGTTCAACGGCACAGTCAAGG-3’
123
R:5’-ACATACTCAGCACCAGCATCACC-3’
Table 2 Molecular docking binding energy
Molecule Name
Binding energy (kcal/mol)
TP53
AKT1
Jun
Caspase-3
MAPK3
MAPK1
Quercetin
-7.3
-6.4
-7.9
-7.9
-7.3
-6.4
Kaempferol
-7.1
-6.3
-7.9
-8.1
-7.1
-6.3
Beta-sitosterol
-7.6
-6.1
-7.3
-8.7
-7.6
-6.1
Luteolin
-7.2
-6.5
-8.6
-8.2
-7.2
-6.5
Stigmasterol
-7
-6.9
-7.6
-7
-7
-6.9
Table 3 Body weight and blood sugar change at different time points (n > 3)
Time (week)
Body weight (g)
Blood glucose (mmol/L)
Control
Model
BQKL
CaD
Control
Model
BQKL
CaD
0
267.00 ± 4.58
277.67 ± 11.68
273.00 ± 24.25
290.67 ± 14.98
7.50 ± 0.66
7.00 ± 0.70
7.77 ± 1.74
7.60 ± 1.08
4
457.00 ± 10.58
312.00 ± 6.08
346.33 ± 5.51
324.00 ± 25.71
7.17 ± 0.45
32.13 ± 0.21
31.60 ± 0.53
31.33 ± 0.15
8
493.67 ± 9.50
323.00 ± 17.35
376.33 ± 11.06
403.00 ± 4.68
8.20 ± 0.36
32.10 ± 0.26
30.90 ± 0.61
30.47 ± 0.38
12
556.00 ± 18.36
295.67 ± 12.01
413.00 ± 16.37
432.67 ± 14.19
8.50 ± 0.26
31.67 ± 0.55
29.50 ± 1.08
27.73 ± 0.76
16
597.00 ± 18.25
260.33 ± 14.84
443.67 ± 24.58
464.00 ± 10.15
7.00 ± 0.26
30.70 ± 0.90
28.23 ± 0.61
25.47 ± 0.74
Table 4 Effect of Buqing granule on blood lipids in rats (n > 3)
Groups
TC (mmol/L)
TG (mmol/L)
Control
1.76 ± 0.07
1.17 ± 0.05
Model
3.01 ± 0.09
3.17 ± 0.14
BQKL
2.69 ± 0.07
2.74 ± 0.06
CaD
2.50 ± 0.05
1.30 ± 0.06
Table 5 Effect of Buqing granule on oxidative stress in rat retinal tissue and serum (n > 3)
Groups
Retinal tissue
Blood serum
SOD (U/mgprot)
MDA (nmol/mgprot)
GSH-Px (U)
SOD (U/mgprot)
MDA (nmol/mgprot)
GSH-Px (U)
Control
467.77 ± 7.50
1.56 ± 0.08
71.15 ± 1.11
547.83 ± 9.27
8.43 ± 0.42
319.44 ± 3.38
Model
95.25 ± 1.41
22.94 ± 2.11
23.55 ± 1.06
347.22 ± 25.72
45.43 ± 0.99
73.80 ± 0.98
BQKL
202.33 ± 1.89
7.69 ± 0.45
54.37 ± 0.67
515.25 ± 11.60
15.41 ± 0.65
179.72 ± 2.58
CaD
228.47 ± 2.19
5.16 ± 0.70
65.88 ± 0.44
530.68 ± 3.93
15.56 ± 0.28
243.94 ± 1.95
Citation: Yang YF, Yuan L, Li XY, Liu Q, Jiang WJ, Jiao TQ, Li JQ, Ye MY, Niu Y, Nan Y. Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation. World J Diabetes 2024; 15(9): 1942-1961